The FDA approved Reata Pharmaceuticals Inc’s (NASDAQ:RETA) Skyclarys (omaveloxolone) for Friedreich’s ataxia in adults and adolescents aged 16 and older. With…
Feb. 28 is Rare Disease Day. It's meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia, Cystic Fibrosis and Hemophilia to name a few.
Guggenheim Partners initiated coverage on Structure Therapeutics Inc (NASDAQ:GPCR) with a Buy rating and a price target of $50 based on the multi-billion-dollar…
Needham increased the price target for Revolution Medicines Inc (NASDAQ:RVMD) from $32 to $38 with a Buy rating. In its Q4 earnings release, Revolution…
Merck & Co Inc (NYSE:MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda (pembrolizumab) in combination with enzalutamide and androgen…